PTK2 and metastatic melanoma: In this study, we demonstrate that inhibiting FAK with either siRNA or a small inhibitor targeting the kinase domain while decreasing melanoma cell migration led to increased invadopodia activity in metastatic melanoma, but not in in situ melanoma.